|
Jul 1
|
ALKS or CSLLY: Which Is the Better Value Stock Right Now?
|
|
Jun 16
|
U.S. Food and Drug Administration Approves CSL's ANDEMBRY® (garadacimab-gxii), the Only Prophylactic Hereditary Angioedema (HAE) Treatment Targeting Factor XIIa with Once-Monthly Dosing for All Patients From the Start
|
|
Jun 13
|
Life Sciences Investor Forum: Now Available for Online Viewing
|
|
Jun 10
|
Life Sciences Investor Forum Agenda Announced for June 11th-12th
|
|
Feb 20
|
CSL Receives Approval in Japan for ANDEMBRY® (garadacimab) Subcutaneous (S.C.) Injection 200mg Pens, a Novel Human Anti-Activated Factor XII Monoclonal Antibody for the Prevention of Acute Attacks of Hereditary Angioedema (HAE)
|
|
Jan 10
|
Is CSL Limited (ASX:CSL) Trading At A 30% Discount?
|